Aralez Pharmaceuticals Inc (NASDAQ:ARLZ) announced its quarterly earnings results on Tuesday. The company reported ($0.42) EPS for the quarter, missing the Zacks’ consensus estimate of ($0.40) by $0.02. Aralez Pharmaceuticals had a negative net margin of 211.76% and a negative return on equity of 65.67%. The company had revenue of $26 million during the quarter, compared to analyst estimates of $20.23 million. During the same quarter last year, the company posted ($0.73) EPS. The firm’s quarterly revenue was up 221.0% on a year-over-year basis.
Aralez Pharmaceuticals (NASDAQ:ARLZ) traded down 6.88% during mid-day trading on Friday, reaching $1.49. 536,353 shares of the company’s stock were exchanged. Aralez Pharmaceuticals has a 52-week low of $1.14 and a 52-week high of $6.80. The stock’s market cap is $97.87 million. The company has a 50-day moving average of $1.60 and a 200-day moving average of $3.52.
A number of research analysts recently commented on ARLZ shares. Bloom Burton upgraded shares of Aralez Pharmaceuticals from an “accumulate” rating to a “buy” rating in a research note on Monday, April 10th. Chardan Capital decreased their price target on shares of Aralez Pharmaceuticals from $10.00 to $5.50 and set a “buy” rating on the stock in a research note on Wednesday, March 15th.
In other Aralez Pharmaceuticals news, Director Arthur S. Kirsch acquired 45,000 shares of the stock in a transaction dated Wednesday, March 15th. The stock was purchased at an average cost of $2.27 per share, for a total transaction of $102,150.00. Following the acquisition, the director now owns 149,109 shares in the company, valued at approximately $338,477.43. The acquisition was disclosed in a filing with the SEC, which is accessible through this hyperlink. Also, CEO Adrian Adams acquired 500,000 shares of the stock in a transaction dated Wednesday, March 15th. The stock was acquired at an average price of $2.46 per share, with a total value of $1,230,000.00. Following the completion of the acquisition, the chief executive officer now owns 3,569,230 shares in the company, valued at approximately $8,780,305.80. The disclosure for this purchase can be found here. Over the last quarter, insiders have acquired 549,750 shares of company stock valued at $1,342,173. 6.77% of the stock is currently owned by company insiders.
Several large investors have recently made changes to their positions in ARLZ. Isthmus Partners LLC raised its stake in shares of Aralez Pharmaceuticals by 4.9% in the first quarter. Isthmus Partners LLC now owns 153,102 shares of the company’s stock worth $328,000 after buying an additional 7,110 shares during the last quarter. Wsfs Capital Management LLC purchased a new stake in Aralez Pharmaceuticals during the fourth quarter worth approximately $474,000. Norges Bank purchased a new stake in Aralez Pharmaceuticals during the fourth quarter worth approximately $665,000. Armistice Capital LLC raised its stake in Aralez Pharmaceuticals by 35.0% in the fourth quarter. Armistice Capital LLC now owns 2,836,000 shares of the company’s stock worth $12,507,000 after buying an additional 736,000 shares in the last quarter. Finally, Glacier Peak Capital LLC raised its stake in Aralez Pharmaceuticals by 122.6% in the fourth quarter. Glacier Peak Capital LLC now owns 102,400 shares of the company’s stock worth $452,000 after buying an additional 56,400 shares in the last quarter. Hedge funds and other institutional investors own 44.01% of the company’s stock.
COPYRIGHT VIOLATION WARNING: This piece was first posted by Chaffey Breeze and is the sole property of of Chaffey Breeze. If you are reading this piece on another website, it was stolen and reposted in violation of United States & international trademark and copyright law. The legal version of this piece can be accessed at https://www.chaffeybreeze.com/2017/05/20/aralez-pharmaceuticals-inc-arlz-announces-earnings-results-misses-expectations-by-0-03-eps-updated.html.
Aralez Pharmaceuticals Company Profile
Aralez Pharmaceuticals Inc is a Canada-based specialty pharmaceutical company. The Company focuses on acquiring, developing and commercializing products in cardiovascular, pain and other areas. The Company’s products include Fibricor, Cambia, Fiorinal, Fiorinal C, Soriatane, Bezalip SR, NeoVisc, Uracyst, Durela, Proferrin, Resultz and Collatamp G.
Receive News & Ratings for Aralez Pharmaceuticals Inc Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Aralez Pharmaceuticals Inc and related companies with MarketBeat.com's FREE daily email newsletter.